DCTH

Business Context and Reporting Period

Company: Delcath Systems, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Stage: Development Stage Company
Overview: Delcath is developing a proprietary drug delivery system for high-dose chemotherapy to treat liver cancer (specifically malignant melanoma metastasized to the liver) using the agent Melphalan. The company has no commercial revenues and relies on equity financing to fund clinical trials and operations.

Key Financial Metrics

Key Expense Drivers (9 Months 2007):

• Research and Development: $3,208,963
• General and Administrative: $2,183,043
• Derivative Instrument Expense: $78,000

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the nine months ended September 30, 2007, decreased by 30.6% compared to the same period in 2006. This improvement is primarily attributed to the resolution of significant legal matters in 2006 that incurred substantial costs.
• Expense Shifts: While General and Administrative expenses dropped 63.9% year-over-year due to lower legal fees, Research and Development costs increased 71.8%. This increase is driven by a five-fold increase in annual payments to the National Cancer Institute (NCI) under an extended Cooperative Research and Development Agreement (CRADA) and accelerated clinical development costs.
• Liquidity Improvement: Cash and cash equivalents increased from $6.3 million at December 31, 2006, to $18.5 million at September 30, 2007. This was fueled by a registered direct offering in September 2007 yielding net proceeds of approximately $13.3 million and option exercises.
• Derivative Liability: A new current liability of $4,347,000 was recorded for warrants issued in the September 2007 offering, classified as a derivative instrument liability subject to mark-to-market adjustments.

Outlook, Risks, and Management Commentary

Clinical Trial Suspension (Critical Risk): On October 22, 2007 (post-period end), the FDA recommended a temporary suspension of enrollment in the Company's Phase III and Phase II clinical trials. This follows reports of four serious adverse gastrointestinal (GI) events potentially related to Melphalan infusion. The Company voluntarily deferred accrual of new patients to analyze adverse events and meet with the FDA. There is no assurance regarding when or if enrollment will resume.

Liquidity and Capital Resources: Management believes current capital ($19.05 million in cash, cash equivalents, and CDs) is sufficient to complete existing Phase II and Phase III trials. However, the company remains dependent on future equity or debt sales to fund operations, as it has no revenue and expects to continue incurring losses.

Other Risks:

• Regulatory: Potential for permanent clinical hold or failure to resolve safety concerns.
• Listing Compliance: The Company is currently compliant with NASDAQ Capital Market requirements but must maintain specific stock price, float, and corporate governance standards to avoid delisting.
• Accounting: Significant non-cash expenses related to stock-based compensation and derivative liability adjustments.

Investor Verification Checklist

• FDA Status: Verify the outcome of the FDA meeting regarding the suspension of Phase II and Phase III trials and the timeline for resuming patient enrollment.
• Cash Burn Rate: Monitor the rate of cash consumption given the suspension of trials and the increased NCI payments to ensure the $18.5 million cash balance remains sufficient.
• Derivative Liability: Track the mark-to-market adjustments on the $4.35 million warrant liability, as fluctuations in stock price will impact reported net loss.
• Legal Proceedings: Confirm the status of the appeal filed by the defendant in the libel case dismissed in April 2007.
• Equity Dilution: Assess the impact of the September 2007 offering (3.8 million shares + warrants) and future potential financing needs on shareholder dilution.